Acupuncture point application agent as well as preparation method and application thereof

Abstract

The invention discloses an acupoint patch as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The acupoint application agent comprises a traditional Chinese medicine composition, and the traditional Chinese medicine composition is prepared from, by mass, 8-12 parts of raw semen brassicae, 8-12 parts of raw rhizoma pinelliae, 3-8 parts of herba asari, 8-12 parts of semen armeniacae amarae, 8-12 parts of cortex cinnamomi and 3-8 parts of euphorbia kansui. The acupoint application agent and the lung tonifying decoction are taken as a traditional Chinese medicine combined preparation for oral administration and external use and are applied to preparation of medicines for treating lung and kidney qi deficiency type COPD in the stable phase. The combined application of the acupoint application agent and the lung tonifying decoction can tonify lung and kidney, relieve cough and reduce sputum, achieve the purposes of treating COPD stable phase and improving prognosis, has the comprehensive advantages of safety, effectiveness and economy, can well solve the current situation that clinical medicine is insufficient in clinical severe acute attack light stable phase and COPD stable phase, and has wide application prospects.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to an acupoint patch and a preparation method and application thereof. Background Art

[0002] Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease characterized by persistent airflow limitation and corresponding respiratory symptoms, manifested as a progressive decline in lung function. COPD has a high prevalence, a long course of disease, a high disability rate, and is chronically progressive and irreversible. If it cannot be controlled, it will lead to serious consequences such as cor pulmonale and cardiopulmonary failure. Moderate to very severe COPD imposes a considerable economic burden on patients. According to statistics, COPD has become the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Importantly, most of the disease burden and healthcare utilization of COPD are related to its comorbidities (such as skeletal muscle atrophy, ischemic heart disease, cognitive dysfunction) and the treatment of acute exacerbations of infectious viruses and bacteria.

[0003] COPD can be divided into acute exacerbation and stable phases according to the severity of onset. Its treatment is a continuous and long process. However, clinicians and patients often pay more attention to the treatment of acute exacerbation, while the management and conditioning of the stable phase are often neglected. In fact, the stable phase of COPD is an important stage in its management. At this stage, it is particularly important to choose the right time for treatment, use the right therapeutic drugs, and find effective auxiliary treatments. Therefore, effective management during the stable phase can improve the quality of life, relieve symptoms, reduce the severity of acute exacerbations, and reduce the frequency of hospitalization. Summary of the invention

[0004] In view of the above-mentioned prior art, the present invention provides an acupoint patch and a preparation method and application thereof. Through the combined application of the acupoint patch and Bufei Decoction, the lungs and kidneys are tonified, cough and phlegm are relieved, and the purpose of treating COPD in the stable period and improving the prognosis is achieved. In addition, the acupoint patch has the comprehensive advantages of safety, effectiveness and economy, and can well solve the current situation of insufficient clinical medication in the mild stable period of severe acute exacerbation and the stable period of COPD, and has broad application prospects.

[0005] In order to achieve the above-mentioned purpose, the technical solution adopted by the present invention is: to provide an acupoint patch, the acupoint patch comprises a Chinese medicine composition, the Chinese medicine composition comprises the following raw materials in parts by weight: 8 to 12 parts of raw mustard seeds, 8 to 12 parts of raw pinellia, 3 to 8 parts of asarum, 8 to 12 parts of bitter almonds, 8 to 12 parts of cinnamon and 3 to 8 parts of kansui.

[0006] Based on the above technical solution, the present invention can also be improved as follows.

[0007] Furthermore, the Chinese medicine composition includes the following raw materials in parts by weight: 10 parts of raw mustard seeds, 10 parts of raw pinellia tuber, 5 parts of asarum, 10 parts of bitter almonds, 10 parts of cinnamon bark and 5 parts of kansui.

[0008] The beneficial effect of the above further technical scheme adopted by the present invention is: in this formula, raw mustard and raw pinellia are used as the main medicine together; raw mustard is pungent and warm, can resolve phlegm and expel fluid, dissipate stagnation and reduce swelling, and has significant curative effect on the symptoms of cold phlegm cough, chest and rib distension and other symptoms in chronic obstructive pulmonary disease; raw pinellia is also pungent and warm, has the effects of drying dampness and resolving phlegm, eliminating lumps and dissipating stagnation, and can directly treat the symptoms of phlegm and dampness blocking the lungs, cough and asthma of chronic obstructive pulmonary disease; the combination of the two strengthens the effect of removing phlegm and relieving asthma, and directly targets the main pathogenesis of chronic obstructive pulmonary disease. Bitter almond and asarum are used as ministerial medicines; bitter almond is bitter and warm, can descend qi to relieve cough and asthma, moisten the intestines and relieve constipation, and directly treat the cough and asthma symptoms of chronic obstructive pulmonary disease, and enhance the antitussive and antiasthmatic effect of the main medicine; asarum is pungent and warm, can dispel wind and cold, open the orifices and relieve pain, warm the lungs and resolve fluid, and its effect of warming the lungs and resolving fluid complements the main medicine, further strengthens the expectorant effect, and helps to relieve cough and asthma caused by cold evil. Cinnamon and gansui act as adjuvants; cinnamon is pungent, sweet and hot, can replenish yang, warm the spleen and stomach, remove cold accumulation, and dredge blood vessels. Its warming yang effect helps to dispel the cold evil in the body, restrict the excessive pungent and dispersing nature of some drugs in the main and auxiliary drugs, and play an adjuvant role; gansui is bitter, cold and toxic, and can purge water, expel fluid, reduce swelling and disperse knots. Although its purgative effect does not directly target the main symptoms of COPD, it can indirectly alleviate symptoms such as cough and asthma caused by water retention by eliminating water in the body. This formula aims to warm the lungs and eliminate phlegm, relieve cough and relieve asthma through reasonable drug compatibility, and is suitable for the adjuvant treatment of COPD.

[0009] Furthermore, the preparation method of the acupoint patch comprises the following steps: the Chinese medicine composition is made into powder, and then mixed with fresh ginger juice to form a paste.

[0010] Furthermore, the acupoint patch is used in the preparation of a medicine for treating COPD of the lung-kidney qi deficiency type in the stable stage.

[0011] Furthermore, the medicine consists of an internal medicine and an external medicine, the internal medicine is a lung-boosting soup, and the external medicine is an acupoint patch.

[0012] Furthermore, the lung-boosting soup comprises the following raw materials in parts by weight: 5-7 parts of ginseng, 5-7 parts of astragalus, 5-7 parts of schisandra, 5-7 parts of aster, 10-14 parts of mulberry bark and 10-14 parts of rehmannia root.

[0013] Further, the lung-boosting soup comprises the following raw materials in parts by mass: 6 parts of ginseng, 6 parts of astragalus, 6 parts of schisandra, 6 parts of aster, 12 parts of mulberry bark and 12 parts of rehmannia root.

[0014] The beneficial effect of the further technical scheme adopted in the present invention is: using Bufei Decoction combined with acupoint plastering to treat the stable stage of COPD with both lung and kidney deficiency, attacking and replenishing are combined, with replenishing as the main method, taking into account the three internal organs of the lung, spleen and kidney, and fitting the pathogenesis of the stable stage of COPD with deficiency of the root and excess of the symptoms. The combined treatment has pioneered the comprehensive treatment of COPD in the stable stage with traditional Chinese medicine.

[0015] Furthermore, the drug is used during the summer "Three Fu" season and the winter "Three Jiu" season, with a usage cycle of three years.

[0016] The beneficial effect of the further technical scheme adopted by the present invention is: the intervention is carried out during the "Three Dog Days" in summer and the "Three Nine Days" in winter, which is in line with the concept of "treating winter diseases in summer". The Yang Qi is stimulated with twice the result with half the effort during the "Three Dog Days" when the Yang Qi is the most vigorous, and the deficiency and cold diseases often caused by insufficient Yang Qi in winter are treated by the method of replenishing Qi and tonifying Yang, unblocking the meridians and activating the collaterals; and the Yang Qi is effectively protected during the "Three Nine Days" when the Yin Qi is vigorous and the Yang Qi is latent, so that it cannot leak out, thereby playing the effect of preventing and curing diseases. It has been used for three consecutive years, with a long cycle, which is in line with the characteristics of long course of chronic diseases.

[0017] The beneficial effects of the present invention are as follows: the comprehensive treatment scheme of Bufei Decoction combined with acupoint application fully recognizes the fundamental pathogenesis of lung and kidney deficiency and phlegm turbidity in the stable period of COPD, and achieves the purpose of treating the stable period of COPD and improving the prognosis by tonifying the lung and kidney, relieving cough and reducing phlegm, and has the comprehensive advantages of safety, effectiveness and economy, which can well solve the current situation of insufficient clinical medication in the light stable period of severe acute attack and stable period of COPD, and has broad application prospects. Bufei Decoction combined with acupoint application treats the stable period of COPD with lung and kidney deficiency, forming a complete set of treatment schemes for improving the prognosis of COPD with traditional Chinese medicine, which is of great significance to improving the quality of life and prognosis of COPD patients and forming a comprehensive treatment scheme of internal and external treatment of traditional Chinese medicine. DETAILED DESCRIPTION

[0018] The specific implementation modes of the present invention are described in detail below with reference to the embodiments.

[0019] Example 1 An acupoint patch is prepared by the following steps: Weigh 10g of raw mustard seeds, 10g of raw pinellia, 5g of asarum, 10g of bitter almonds, 10g of cinnamon and 5g of kansui, dry the above Chinese medicines, grind them into powder of about 100 mesh, then mix them evenly with appropriate amount of water and fresh ginger juice, and prepare them into a paste. Take an appropriate amount each time and fix it with medical glue.

[0020] Example 2 An acupoint patch is prepared by the following steps: Weigh 8g of raw mustard seeds, 8g of raw pinellia, 3g of asarum, 8g of bitter almonds, 8g of cinnamon and 3g of kansui, dry the above Chinese medicines, grind them into powder of about 100 mesh, then mix them evenly with appropriate amount of water and fresh ginger juice, and prepare them into a paste. Take an appropriate amount each time and fix it with medical glue.

[0021] Example 3 An acupoint patch is prepared by the following steps: Weigh 12g of raw mustard seeds, 12g of raw pinellia, 8g of asarum, 12g of bitter almonds, 12g of cinnamon and 8g of kansui, dry the above Chinese medicines, grind them into powder of about 100 mesh, then mix them evenly with appropriate amount of water and fresh ginger juice, and prepare them into a paste. Take an appropriate amount each time and fix it with medical glue.

[0022] Example 4 A combined preparation of Chinese medicine for internal and external use, comprising an acupoint plaster and a decoction.

[0023] The formula and preparation method of the acupoint patch are the same as those in Example 1.

[0024] The decoction is a lung-boosting decoction, which includes the following raw materials: 6g of ginseng, 6g of astragalus, 6g of schisandra, 6g of aster, 12g of mulberry bark and 12g of prepared rehmannia. The components of the lung-boosting decoction are prepared in the form of decoction-free granules according to dosage and are taken immediately after mixing.

[0025] Example 5 A combined preparation of Chinese medicine for internal and external use, comprising an acupoint plaster and a decoction.

[0026] The formula and preparation method of the acupoint patch are the same as those in Example 2.

[0027] The decoction is a lung-boosting decoction, which includes the following raw materials: 5g of ginseng, 5g of astragalus, 5g of schisandra, 5g of aster, 10g of mulberry bark and 10g of prepared rehmannia. The components of the lung-boosting decoction are prepared in the form of decoction-free granules according to the dosage and are taken immediately after mixing.

[0028] Example 6 A combined preparation of Chinese medicine for internal and external use, comprising an acupoint plaster and a decoction.

[0029] The formula and preparation method of the acupoint patch are the same as those in Example 3.

[0030] The decoction is a lung-boosting decoction, which includes the following raw materials: 7g of ginseng, 7g of astragalus, 7g of schisandra, 7g of aster, 14g of mulberry bark and 14g of prepared rehmannia. The components of the lung-boosting decoction are prepared in the form of decoction-free granules according to dosage and are taken immediately after mixing.

[0031] The performances of the combined preparations of Chinese medicine for internal and external use obtained in Examples 4 to 6 are similar. Taking Example 4 as an example, the performances of the acupoint patch and the lung-boosting soup are described in detail.

[0032] Application Examples 1. A total of 120 patients with stable COPD who were treated in the outpatient and hospital settings of the Institute of Traditional Chinese Medicine, Sichuan Academy of Traditional Chinese Medicine (Sichuan Second Hospital of Traditional Chinese Medicine) and were diagnosed with lung and kidney qi deficiency by TCM dialectics were collected. SPSS 26.0 was used to generate random numbers using a random number table method, and random allocation cards were made and placed in opaque envelopes and arranged in sequence. When patients who met the inclusion criteria entered this study, the envelopes with the same sequence number were opened in the order of inclusion to determine the grouping. Finally, they were randomly divided into four groups: control group, decoction group, plaster group, and decoction + plaster group, so that there were no significant differences in age, course of disease, severity, and education level among the patients in each group.

[0033] 2. Diagnostic criteria (1) Western medicine disease diagnostic criteria Western medicine diagnosis and staging standards are mainly based on the "Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (2021 Revised Edition)" specified by the Chronic Obstructive Pulmonary Disease Group of the Respiratory Medicine Branch of the Chinese Medical Association.

[0034] ① Chronic cough, sputum or wheezing, chest tightness, and dyspnea for two consecutive years or more; ② Recurrent episodes or (and) a history of recurrent lower respiratory tract infection for two consecutive years or more; ③ Imaging examinations show signs of chronic bronchitis or (and) emphysema; ④ After using bronchodilators, FEV 1 / FVC is less than 70%.

[0035] COPD can be diagnosed if one of ①②③ and ④ are present.

[0036] If symptoms such as cough, sputum, and shortness of breath are mild or stable and last for more than 1 month, it can be diagnosed as stable COPD.

[0037] (2) TCM syndrome diagnostic criteria The diagnostic criteria for lung and kidney qi deficiency syndrome mainly refer to the TCM Syndrome Diagnostic Criteria for Chronic Obstructive Pulmonary Disease (2011 Edition) of the Pulmonary Disease Professional Committee of the Internal Medicine Branch of the Chinese Association of Traditional Chinese Medicine.

[0038] Main symptoms: wheezing, shortness of breath, aggravated by movement, fatigue, weakness, soreness of waist and knees, easy to catch cold, light tongue coating, white tongue coating, thin pulse. Secondary symptoms: aversion to wind, spontaneous sweating, puffy face, chest tightness, dizziness, tinnitus, frequent urination, frequent urination at night, coughing and nocturnal enuresis, enlarged tongue with teeth marks, deep and weak pulse.

[0039] ① Wheezing and shortness of breath, aggravated by movement; ② Fatigue or spontaneous sweating, aggravated by movement; ③ Prone to colds and aversion to wind; ④ Weakness in waist and knees; ⑤ Tinnitus or dizziness or puffy complexion; ⑥ Frequent urination, frequent urination at night, or coughing and enuresis; ⑦ Pale tongue, white tongue coating, or deep and thin or weak pulse.

[0040] The diagnosis can be made if 2 of ①②③ are met and 2 of ④⑤⑥⑦ are met.

[0041] 3. Inclusion and exclusion, dropout, and elimination criteria (1) Inclusion criteria ① Meet the above-mentioned Western medical disease diagnosis criteria and TCM syndrome diagnosis criteria and have a stable condition for more than 1 month; ② Willing to accept Chinese medicine plus acupoint application treatment; ③ No other chronic diseases that may affect the study; ④ Lung function indicates mild, moderate or severe obstructive pulmonary function, and no routine use of hormones, bronchodilators and other Western medicine maintenance treatment is required during the remission period; ⑤ Have a certain level of education, can understand the research plan and its value, and can truthfully fill in the questionnaire and scale survey; ⑥ Have not participated in other clinical research in the past year; ⑦ Based on the principle of voluntariness, agree to cooperate and accept the questionnaire and scale survey, and sign the informed consent form.

[0042] (2) Exclusion criteria ① Those who have had upper respiratory tract infection in the past 2 weeks; ② Those who are in the stable stage of other respiratory diseases other than COPD; ③ Those who have serious primary diseases such as cardiovascular and cerebrovascular diseases and cannot cooperate with pulmonary function tests; ④ Those with severe hearing, speech, cognitive dysfunction or mental illness; ⑤ Those with poor compliance, unable to take medicine on time, or unable to complete acupoint application on time; ⑥ Those who suffer from other chronic diseases and are taking drugs that may affect the study; ⑦ Those with allergic constitutions; ⑧ Those who are unwilling or unable to accept the research measures and cannot cooperate for other reasons.

[0043] (3) Shedding standard ① Those who lost contact before completing the study; ② Those who voluntarily proposed to withdraw from the study; ③ Those who have completed more than two-thirds of the study and have complete data collection should be included in the study.

[0044] (4) Elimination criteria ① Those who have serious adverse reactions; ② Those who violate the study protocol; ③ Those who have serious comorbidities, complications, or other diseases unrelated to this study during the study and are not suitable to continue the study.

[0045] 4. Treatment options 120 patients with stable COPD who met the inclusion criteria were randomly divided into 4 groups, 30 cases in each group. The control group was given oral Chinese medicine placebo plus sham acupoint application, the decoction group was given oral Bufei decoction plus sham acupoint application, the application group was given oral Chinese medicine placebo plus acupoint application, and the decoction + application group was given oral Bufei decoction plus acupoint application; the decoction was one dose per day, and the acupoint application was twice a week. The intervention time was around the "three-fu" period in summer and the "three-nine" period in winter each year, and the intervention time was 4 weeks per season for three consecutive years.

[0046] When using acupoint patches, the main acupoints are Feishu and Shenshu to nourish the lungs and kidneys. The lungs control qi, and the kidneys absorb qi. The qi of the lungs and kidneys is regulated and replenished to strengthen the lung qi, inhale the clear and exhale the turbid, and absorb qi into the kidneys; the auxiliary acupoints are Fengmen and Dingchuan, which can resolve phlegm and relieve cough; Fenglong and Zusanli can be used to strengthen the spleen and resolve phlegm; Taixi and Guanyuan can be used to replenish the kidney's essence.

[0047] 5. Observation indicators The changes of various indicators before and after treatment in each group of patients were collected, and the patients' conditions were evaluated in time to observe whether adverse reactions and acute exacerbations occurred, and to determine whether the study could continue. The observation indicators were the frequency, duration, degree, symptoms, quality of life, inflammatory indicators and lung function of acute COPD attacks in the four groups of patients before and after treatment, in order to evaluate the safety and clinical efficacy of Bufei Decoction combined with acupoint application for COPD patients.

[0048] (1) General observation items Record the patient's name, gender, age, medical history, etc.

[0049] (2) Safety indicators ① Basic vital signs; ② Laboratory examination: three routine tests, liver and kidney function; ③ Electrocardiogram.

[0050] (3) Efficacy indicators ① Pulmonary function: The pulmonary function of each group of patients was tested before and after treatment, mainly observing FEV 1 %pred, FEV 1 / FVC index, and collected and recorded (the location was in the pulmonary function room of Sichuan Second Hospital of Traditional Chinese Medicine, completed by a dedicated person in the pulmonary function room, the pulmonary function instrument was produced by Germany Kangxun, model PowerCube. Body). The pulmonary function classification of the severity of airflow limitation in patients with COPD is shown in Table 1.

[0051] Table 1 Pulmonary function classification of severity of airflow limitation in patients with COPD

[0052] Note: FEV after inhalation of bronchodilator 1 / FVE<70% ② Degree of dyspnea: Inform the patient of the content and significance of the questionnaire. The dyspnea questionnaire is shown in Table 2. Collect and record the mMRC scores before and after treatment according to the actual situation.

[0053] Table 2 Modified British Medical Research Council Dyspnea Questionnaire

[0054] ③ Six-minute walk test: inform the patient of the content and significance of the test, strictly perform 6MWT according to the standard, and collect and record the six-minute walking distance before and after treatment (refer to the 6MWT application guidelines formulated by ATS in 2002). The 6-minute walk test scores are shown in Table 3.

[0055] Table 3 6-minute walk test scores

[0056] ④Chronic obstructive pulmonary disease assessment test: Carefully inform the patient of the test content, let them fill in the scores according to the actual situation, collect and record the total score of CAT before and after treatment, and the chronic obstructive pulmonary disease assessment test score is shown in Table 4. Carefully inform the patient of the test content, let them fill in the scores according to the actual situation, collect and record the total score of CAT before and after treatment, and the chronic obstructive pulmonary disease assessment test score is shown in Table 4.

[0057] Table 4 COPD Assessment Test Scores

[0058] ⑤ TCM syndrome scoring scale: inform the patient of the content and significance of the scale. The TCM syndrome scoring scale for COPD is shown in Table 5. Ask the patient about various symptoms in detail before and after treatment, and collect and record the scores of each single syndrome and the total score (developed with reference to the Guiding Principles for Clinical Research of New Chinese Medicines).

[0059] Table 5 TCM syndrome score table for COPD

[0060] ⑥Inflammatory indicators: The ELISA method was used to detect the levels of IL-10, IL-6, IL-8, NF-κB, and TNF-α inflammatory factors in the peripheral blood of patients before and after treatment.

[0061] 6. Statistical Analysis SPSS 26.0 software was used for statistical analysis in this study.

[0062] 7. TCM syndrome and efficacy evaluation criteria According to the nimodipine method: efficacy index = [(post-treatment score - pre-treatment score) / pre-treatment score] × 100%, divided into four levels: clinical control, marked effect, effective, and ineffective. The scoring standard is formulated with reference to the "Guidelines for Clinical Research of New Chinese Medicines", and the change of TCM syndrome score before and after is used as the standard for judging the efficacy of the disease. The efficacy evaluation standard is as follows: (1) Clinical control: clinical symptoms and signs disappear or almost disappear, and syndrome score decreases by ≥95%; (2) Significantly effective: clinical symptoms and signs were significantly improved, with syndrome score reduction of 70% ≤ < 95%; (3) Effective: clinical symptoms and signs improved, with syndrome score reduced by 30% ≤ <70%; (4) Ineffective: There is no significant improvement in clinical symptoms and signs, or they may even worsen, and the symptom score decreases by less than 30%.

[0063] 8. Observation of therapeutic effects (1) The pulmonary function classification of the severity of airflow limitation in COPD patients before and after treatment is shown in Table 6. After statistical analysis, the pulmonary function classification of the decoction + patch group was significantly improved compared with the control group and the patch group after treatment.

[0064] Table 6 Statistics of lung function classification before treatment

[0065] (2) The mMRC scores before and after treatment are shown in Table 7. After statistical analysis, the mMRC scores of the decoction + patch group were significantly improved compared with those of the control group.

[0066] Table 7 Statistics of mMRC scores before and after treatment

[0067] (3) The results of the six-minute walk test before and after treatment are shown in Table 8. After statistical analysis, the results of the six-minute walk test in the decoction + patch group were significantly improved compared with the control group after treatment.

[0068] Table 8 Statistical results of the six-minute walk test before and after treatment

[0069] (4) The COPD assessment test scores and TCM syndrome scores before and after treatment are shown in Table 9. After statistical analysis, the COPD scores before and after treatment in the decoction + patch group were significantly better than those in the control group, decoction group and patch group, as * indicates P < 0.05, indicating that the level of reduction in TCM syndrome scores in the decoction + patch group was significantly better than that in the control group, decoction group and patch group; the TCM syndrome scores before and after treatment in the decoction + patch group were significantly better than those in the control group, decoction group and patch group, as * indicates P < 0.05, indicating that the level of reduction in TCM syndrome scores in the decoction + patch group was significantly better than that in the control group, decoction group and patch group.

[0070] Table 9 Changes in COPD scores and TCM syndrome score indicators before and after treatment

[0071] (5) Changes of inflammatory indexes before and after treatment are shown in Table 10. The levels of IL-6, IL-8, IL-10 and TNF-α in the decoction + patch group were compared with those in the control group, decoction group and patch group after treatment. * indicates P < 0.05, indicating that the decoction + patch group was significantly better than the control group, decoction group and patch group in reducing the level of TNF-α.

[0072] Table 10 Changes of inflammatory indicators before and after treatment

[0073] (6) Comparison of clinical efficacy of the four groups of patients after treatment is shown in Table 11. The clinical efficacy of the decoction + patch group was compared with that of the control group, and the decoction group and the patch group. * indicates P < 0.05, indicating that the clinical efficacy of the decoction + patch group was significantly better than that of the control group, the decoction group and the patch group.

[0074] Table 11 Comparison of clinical efficacy before and after treatment

[0075] 9. Conclusion In summary, after the combined application of acupoint patches and Bufei Decoction, patients in the stable phase of COPD showed significant improvements in many aspects, including pulmonary function classification of the severity of airflow limitation in COPD patients, mMRC score of dyspnea, six-minute walk test, chronic obstructive pulmonary disease assessment test, COPD TCM syndrome score and inflammatory indicators.

[0076] Although the specific implementation of the present invention is described in detail in conjunction with the embodiments, it should not be understood as limiting the scope of protection of this patent. Within the scope described in the claims, various modifications and variations that can be made by those skilled in the art without creative work still fall within the scope of protection of this patent.

Claims

1. An acupoint patch, characterized in that: The acupoint patch comprises a traditional Chinese medicine composition, which comprises the following raw materials in parts by weight: 8-12 parts of raw mustard seeds, 8-12 parts of raw pinellia tuber, 3-8 parts of asarum, 8-12 parts of bitter almonds, 8-12 parts of cinnamon bark and 3-8 parts of kansui.

2. The acupoint patch according to claim 1, characterized in that: The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 10 parts of raw mustard seeds, 10 parts of raw pinellia tuber, 5 parts of asarum, 10 parts of bitter almonds, 10 parts of cinnamon bark and 5 parts of kansui.

3. The method for preparing the acupoint patch according to claim 1 or 2, characterized in that: The following steps are involved: The Chinese medicine composition is made into powder, and then mixed with fresh ginger juice to form a paste.

4. Use of the acupoint patch according to claim 1 or 2 in the preparation of a medicament for treating COPD of the lung-kidney qi deficiency type in the stable stage.

5. The use according to claim 4, characterized in that: The medicine consists of an internal medicine and an external medicine, the internal medicine is a lung-boosting decoction, and the external medicine is the acupoint patch.

6. The use according to claim 5, characterized in that: The lung-nourishing soup comprises the following raw materials in parts by weight: 5-7 parts of ginseng, 5-7 parts of astragalus, 5-7 parts of schisandra, 5-7 parts of aster, 10-14 parts of mulberry bark and 10-14 parts of rehmannia root.

7. The use according to claim 6, characterized in that: The lung-nourishing soup comprises the following raw materials in parts by weight: 6 parts of ginseng, 6 parts of astragalus, 6 parts of schisandra, 6 parts of aster, 12 parts of mulberry bark and 12 parts of rehmannia root.

8. The use according to any one of claims 4 to 7, characterized in that: The medicine is used during the summer "Three Dogs" and the winter "Three Nines", with a usage cycle of three years.

Images